move beyond amyloid hypothesi
alzheim diseas initi buy pt
steadfast trust rage bullish vtv share
base follow point compani focu evalu
vtv lead product azeliragon mild alzheim diseas ad patient
diabet strategi optim azeliragon chanc success
target receptor advanc glycat end product
rage differenti azeliragon fail amyloid-direct
strategi litter landscap ad drug develop
promis earli potenti demonstr agata
phase studi help patient type type diabet
achiev diseas control materi de-risk vtv early-
stage product pipelin asset via out-licens agreement pharma
compani motiv advanc develop certain territori
outsid expect result june part phase
portion on-going studi posit
catalyst stock therefor initi coverag buy rate
price target
evalu azeliragon mild ad patient diabet optim
potenti success clinic advanc vtv current
clinic develop strategi evalu azeliragon mild ad patient
type diabet patient popul increas rage
express support result azeliragon steadfast
phase trial patient mild ad azeliragon fail show benefit
overal mild ad popul howev post-hoc analysi
azeliragon demonstr signific activ subgroup patient
compris mild ad patient type diabet specif
treatment azeliragon result signific clinic benefit
delay declin cognit function well stabil
whole brain volum vtv focu evalu azeliragon
subgroup ad patient think compani optim
drug chanc success look result azeliragon proof-
of-concept phase studi expect initi june
top-lin result expect confirm posit result
observ azeliragon steadfast
rage differenti mere amyloid-direct strategi
ad progress neurodegen disord slowli destroy
memori think skill eventu abil carri
abnorm progress impair activ daili live
host behavior neuropsychiatr symptom alzheim
top lead caus death known treatment cure
slow progress diseas ad also expens diseas
 cost estim expect cost
much exact caus ad unknown howev
genet environment factor establish contributor
so-cal amyloid hypothesi accumul deposit
amyloid peptid primari caus alzheim diseas
mainstream concept underli alzheim research
year howev attempt develop a-target drug
treat alzheim end failur think rage target
azeliragon offer opportun altern approach
definit distribut analyst rate analyst certif disclosur pleas refer page report
think prior track design azeliragon support potenti favor regulatori pathway current
plan call one addit phase trial azeliragon compris sole mild ad patient diabet defin
baselin motiv grow epidem alzheim diseas medic challeng
diseas present drug develop fda interest help new treatment ad gain approv
thu think notabl azeliragon previous grant track design fda think azeliragon
abil manifest widespread therapeut benefit hint disease-modifi effect ad possibl complet
azeliragon pathway approv may achiev singl trial subgroup ad patient look posit result
proof-of-concept poc phase portion plan phase studi studi mild ad patient
lead advanc azeliragon pivot phase studi earli look complet
pivot phase studi azeliragon lead potenti approv treatment ad patient
project azeliragon achiev annual sale world-wide
favor profil diabet support strong evid base compris clinic
trial includ agata multi-cent adapt phase random double-blind placebo- activ sitagliptin
control parallel group trial evalu safeti efficaci follow six month administr
subject subject stabl dose metformin agata primari endpoint chang
baselin six month initi top-lin result announc august agata show treatment daili
administr mg result statist signific chang baselin six month
reduct dose-depend sustain throughout durat studi well-toler
advers event sever hypoglycemia hyperlipidemia report group novemb
vtv initi adapt phase trial assess pharmacokinet pharmacodynam
safeti toler adult patient design evalu whether well-toler
administ add-on insulin therapi improv daili glucos profil peopl live
vtv complet enrol part learn phase phase portion studi design double-
blind placebo-control studi evalu week daili dose mg chang
expect result june part phase portion studi posit catalyst stock
think complet clinic develop could complet without outcom studi vtv
begun start-up activ part confirm phase phase portion expect report
result late expect result portion studi posit catalyst stock
look vtv conduct end-of-phas meet fda lead approv initi pivot phase
trial adult note due larg patient popul involv chronic natur
treatment diabet natur expect regulatori approv requir outcom studi accept
standard industri outcom studi often take three year complet involv thousand patient
prior market author howev expect clinic develop follow regulatori path navig
rate zynquista inhibitor market treatment
europ gain ema approv septemb without support outcom studi look regulatori
approv estim annual sale could achiev
remaind product pipelin compris early-stag asset whose develop think materi
de-risk via synergist out-licens agreement vtv product pipelin contain early-stag asset
includ contribut model think vtv unlock
valu asset form licens agreement return moder payment vtv grant partner
right product candid certain territori vtv retain right europ japan
vtv primari market interest think payment materi de-risk vtv early-stag asset partner
either sole respons develop case reneo newsoara
respect case huadong sole respons late-stag develop product
candid navig foreign licens countri regulatori process initi partnership requir vtv
advanc product candid mid-stag clinic trial think vtv agreement partner notabl
show synergist relationship think provid best chanc near-term advanc asset provid
vtv data compani could use attract partner develop rest world
valuat risk pt deriv use weighted-averag cost capit vtv discount free
cash flow fully-tax net incom annual sale royalti payment azeliragon year
divid project number share year account effect share dilut factor
termin growth rate clinic program probabl success risk invest thesi includ failur
clinic trial prove efficaci regulatori requir addit clinic studi futur requir assembl sale
market team failur product show differenti patent expiri invalid need rais addit
fund poor market condit
found vtv therapeut vtvt nasdaq-list clinical-stag biotechnolog compani
focus discov develop oral administ small molecul drug candid treatment
alzheim diseas ad diabet princip offic compani locat high point
north carolina decemb vtv employe least hold graduat
degre includ doctor degre engag full-tim research develop
activ vtv complet ipo juli
compani vtv therapeut trace product pipelin lineag transtech
pharma ttp high point ventur compani found former merck rate
scientist adnan mjalli step ceo succeed current ceo
presid stephen holcomb ttp proprietari drug discoveri technolog yield vtv
alzheim diabet drug candid compani receiv earli invest macandew
 forb hold compani whose portfolio includ wide mix compani includ
cosmet maker revlon rate direct mail advertis compani valassi vci rate
year macandrew invest million ttp vtv combin
debt equiti financ even though vtv stock publicli trade control compani
half share own singl entiti decemb control
approxim combin vote power vtv outstand common stock
vtv lead drug candid azeliragon oral administ small molecul antagonist
target receptor advanc glycat end product rage vtv initi start-up activ
adapt phase trial evalu azeliragon potenti treatment mild ad patient
type diabet vtv current clinic develop strategi evalu azeliragon mild ad
patient type diabet patient popul increas rage express support
result azeliragon steadfast phase trial patient mild ad azeliragon fail
show benefit overal mild ad popul demonstr signific activ subgroup
patient compris mild ad patient type diabet specif treatment azeliragon
result signific clinic benefit delay declin cognit function well
stabil whole brain volum vtv focus evalu azeliragon subgroup ad
vtv also drug candid diabet oral administ liver-select glucokinas
activ gka success complet agata phase clinic trial current
test adapt phase studi conduct partnership juvenil
vtv also clinic develop oral administ non-peptid glucagon-lik
receptor agonist success complet logra phase clinic trial
decemb vtv enter licens agreement hangzhou zhongmei huadong
co ltd huadong huadong obtain exclus sub-licens
licens develop commerci compound vtv agonist program includ
china certain pacif rim countri includ australia south korea japan
lastli vtv also advanc earlier stage program licens agreement
peroxisom prolifer activ receptor delta ppar- agonist undisclos orphan diseas
indic phosphodiesteras type inhibitor drug candid copd
decemb vtv enter licens agreement reneo pharmaceut inc
reneo obtain exclus world-wide sub-licens licens develop commerci
product candid vtv ppar- agonist program includ compound
may vtv enter licens agreement newsoara biopharma co ltd
newsoara obtain exclus sub-licens licens develop commerci vtv
inhibitor program includ compound china pacif rim countri
program evalu modul pathway show potenti activ protect
acut effect radiat contrast-induc renal injuri prevent ischemia-reperfus
injuri well chronic indic respiratori injuri neurodegen diseas
mitochondri myopathi advanc academ collabor
phase maacommerci rightsind targetlead optimizationdiscoverypreclinicalindphas diseaseproduct diabetesworldwid diabetesww xc asia pacif rim partneredwith huadong medicin co diabetesww right grant reneopharmaceut indicationww xc asia pacif rim partneredwith newsoara medicin co activ inhibitorworldwideeventtimingimpactannounc comprehens data agata phase studi patient azeliragon proof-of-concept phase studi confirm result steadfast alzheim diseas patient result part learn phase placebo-control phase studi adult result part confirm phase phase studi adult result proof-of-concept phase studi azeliragon alzheim diseas patient pivot trial azeliragon alzheim diseas patient pivot phase studi result phase studi result pivot trial azeliragon alzheim diseas patient nda azeliragon approv treatment patient alzheim diseas nda approv treatment azeliragon approv fda approv fda vtv therapeut inc
bullish vtv share base follow point compani focu evalu
vtv lead product azeliragon mild alzheim diseas ad patient diabet strategi
optim azeliragon chanc success target receptor advanc glycat end
product rage azeliragon mechan action moa differenti fail amyloid-direct
strategi litter landscap ad drug develop promis earli potenti demonstr
help patient type type diabet achiev diseas control materi
de-risk vtv early-stag product pipelin asset via out-licens agreement pharma
compani motiv advanc develop certain territori outsid
focus evalu azeliragon mild alzheim diseas patient diabet
target popul optim potenti success clinic advanc
vtv current clinic develop strategi evalu azeliragon mild ad patient type
diabet patient popul increas rage express support result
azeliragon steadfast phase trial patient mild ad azeliragon fail show benefit
overal mild ad popul post-hoc analysi found azeliragon demonstr signific activ
subgroup patient compris mild ad patient type diabet specif treatment
azeliragon result signific clinic benefit delay declin cognit function well
stabil whole brain volum vtv focu evalu azeliragon subgroup
ad patient think compani optim drug chanc success look result
azeliragon proof-of-concept phase studi expect initi june top-lin result
expect confirm posit result observ azeliragon steadfast
alzheim diseas diabet share common biolog mechan emerg data suggest
type diabet either directli cofactor contribut significantli onset
progress ad fact rage origin identifi receptor ligand whose
concentr increas patient role rage develop secondari
end-organ complic hypothesi support multipl studi
includ studi spontan diabet gener transfer diabetogen spleen cell
non-obes diabet nod mice inhibit solubl rage srage studi rage-
defici mice reject allogen balb/c islet graft reduc rate compar wild-typ
increas avail rage ligand hyperglycemia also suggest hypothesi
amplif autoimmun respons type diabet observ patient ad
advanc glycat end product accumul parallel develop cognit impair
dementia individu variou vitro vivo anim human clinic studi
also provid evid major risk factor patholog ad two diseas
share common biolog mechan molecular level includ insulin resist impair
glucos metabol -amyloid format oxid stress presenc age
azeliragon design inhibit rage origin design vtv predecessor transtech
pharma compani former partner rate
azeliragon oral bioavail small molecul inhibitor rage vitro studi show
azeliragon inhibit srage bind rage ligand amphoterin amphoterin
also known high-mobl group box regul transcript involv organ
dna play role inflamm cell differenti tumor cell migrat one
member famili involv aspect regul cell prolifer differenti
apoptosi ca ion homeostasi energi metabol inflamm migrat ligand interact
rage produc ro
vtv conduct eight phase three phase two phase clinic trial azeliragon
singl protocol steadfast phase trial random double-blind placebo-
control parallel-group evalu azeliragon patient mild alzheim
steadfast compris two ident independ power studi oper conduct
singl protocol steadfast particularli high profil landscap ad
howev notabl third failur
bodi evid show relationship alzheim diabet provid
strong rational azeliragon advanc group steadfast initi april
pursuant special protocol assess spa agreement fda studi conduct
 certain english-speak foreign countri singl protocol design enrol
mild ad patient total divid equal across two independ sub-studi
subject receiv either mg/day dose azeliragon placebo random one-to-on
basi ad standard care soc part steadfast fail meet either co-
primari efficaci ep cdr-sb note approxim a-
studi subject complet treatment azeliragon b-studi subject complet treatment
part stop time visit approxim top-lin result
announc part studi termin
howev vtv captur import takeaway analysi small subgroup steadfast
post-hoc analysi a-studi subgroup patient defin glycosyl
hemoglobin level baselin clinic diagnosi ad show benefit
treatment azeliragon azeliragon-tr group a-studi also demonstr
point benefit adas-cog rel placebo group nomin statist
signific month treatment azeliragon-tr group a-studi
demonstr benefit cdr-sb rel placebo group month
treatment notabl toler concern identifi differ treatment-
emerg advers effect teae treatment-rel teae seriou side effect death observ
azeliragon treatment versu placebo think focus evalu azeliragon mild
alzheim diseas patient diabet optim chanc success base result vtv
initi start activ adapt phase trial conduct singl protocol studi
evalu azeliragon potenti treatment mild ad patient look
initi patient enrol
think notabl primari endpoint phase part studi adas-cog
versu adas-cog co-primari ep steadfast expect co-primari ep
phase part studi due advanc field studi ad adas-cog
alzheim diseas assess scale-cognit subscal develop origin
assess level cognit dysfunct ad patient howev alzheim said account
advanc field research cognit function shift time
focu pre-dementia popul use adas-cog extend pre-dementia studi
howev concern measur abil detect import chang milder stage
diseas progress delay word recal maze digit cancel task ad
creat adas-cog think posit result adas-cog phase studi azeliragon would
potenti vault azeliragon ahead drug candid develop mild ad
exhibit analysi diabet base cognit deficit adas-cog
current plan call one addit phase trial azeliragon compris sole mild ad
patient diabet defin baselin motiv grow epidem
alzheim diseas medic challeng diseas present drug develop fda
interest help new treatment ad gain approv thu think notabl
azeliragon previous grant track design fda think azeliragon abil
manifest widespread therapeut benefit hint disease-modifi effect ad possibl
complet azeliragon pathway approv may achiev singl trial subgroup ad
patient look posit result proof-of-concept poc phase portion plan
phase studi studi mild ad patient lead advanc
azeliragon pivot phase studi earli look complet pivot phase studi
azeliragon lead potenti approv treatment ad patient
project azeliragon achiev annual sale billion world-wide
rage differenti mere amyloid-direct strategi litter landscap
ad progress neurodegen disord slowli destroy memori think skill
eventu abil carri simpl task symptom includ cognit dysfunct memori
abnorm progress impair activ daili live host behavior
neuropsychiatr symptom alzheim top lead caus death known
treatment cure slow progress diseas ad also expens diseas
cost estim billion expect cost much trillion
exact caus ad unknown howev genet environment factor establish
so-cal amyloid hypothesi accumul deposit amyloid
peptid primari caus alzheim diseas mainstream concept underli
alzheim research howev attempt develop a-target drug treat
alzheim end failur think rage target azeliragon offer opportun
exhibit alzheim diseas brain vs healthi brain
affect ad brain exhibit astrogliosi abnorm increas astrocyt nerv cell atrophi
neuron loss character extens distribut two kind abnorm structur so-cal
senil plaqu neurofibrillari tangl nft shown senil plaqu consist
amyloid fibril compos nft contain bundl pair helic filament tau
microtubule-associ protein promot microtubul polymer stabil
regul phosphoryl precursor protein app transmembran protein associ
neuron develop neurit outgrowth axon thu studi ad pathogenesi
mostli focus tau form senil plaqu nft respect
abnorm structur induc neural degener neuron loss
nft neuro-inflamm brain well plaqu believ main caus
lead loss neuron connect brain find indic main factor
underli progress research drug develop alzheim tau normal
subject acid peptid excis app -secretas bace -secretas
releas outsid cell rapidli degrad remov howev age subject
patholog condit metabol abil degrad decreas peptid may
accumul hydrophob major compon
accumul increas level increas ratio induc
fibril format accumul fibril develop senil plaqu caus neurotox induct
tau patholog lead neuron cell death
discoveri genet mutat app early-onset famili ad appear support amyloid
pathogen mutat app cluster near -secretas -secretas
cleavag site associ increas product chang ratio
format addit app locu duplic caus autosomal-domin early-onset ad cerebr
amyloid angiopathi accumul larg amount moreov famili ad
mutat identifi presenilin compon -secretas mutat
app presenilin close link product process implic product
fibril format central ad
exhibit microscop patholog alzheim diseas
budson solomon memori loss alzheim diseas dementia
earli warn sign problem amyloid hypothesi came studi also initi
use support hypothesi exampl number model use genet modifi mice
produc deposit brain howev although senil plaqu form
mice nft format nerv cell death observ suggest extracellular accumul
fibril intrins cytotox dose induc tau normal metabol
product app toxic normal physiolog condit idea develop
oligom key toxic agent lead new avenu explor howev although
oligom fibril present over-express mice amyloid deposit
senil plaqu format observ brain degener nerv cell neuron loss
impair cognit function well result indic
includ oligom amyloid fibril cytotox lastli variou immunotherapi target
ad model mice effect decreas deposit brain lead improv
actual symptom accumul recent advanc amyloid imag made possibl
find mani normal peopl amyloid deposit well ad patient
amyloid distribut senil plaqu brain elderli non-dement
patient sometim extens dementia patient suggest deposit
phenomenon age direct relat onset
februari high profil epoch phase trial verubecestat merck guid
amyloid hypothesi end disappoint januari roch rhhbi rate
announc discontinu two phase trial crenezumab fulli human monoclon
antibodi march follow failur aducanumab a-
target drug candid jointli develop buy fein partner eisai
esali rate drug candid join long list potenti treatment fail deliv
signific benefit result continu failur investig drug ad billion dollar
invest question amyloid hypothesi root caus ad intensifi past
year except eisai march launch phase studi a-
target drug candid ban roch scarlet on-going open-label extens
phase trial a-target drug candid gantenerumab major pharmaceut compani
scale back alzheim research develop leav leadership hand new
target investig smaller often scientist-l under-fund compani
rage may key move beyond tradit amyloid hypothes believ evid
greatest stimulu increas object amyloid hypothesi disappoint
track record drug target clinic trial accumul evid point involv
receptor advanc glycat end product rage play critic role product
clearanc accumul well format nft failur synapt transmiss
neuron thu direct target central may becom unfavor
rage could key move beyond mere amyloid hypothesi
rage cell-surfac receptor immunoglobulin super famili play varieti import role
cell physiolog patholog condit rage express low level
cell normal physiolog condit howev overexpress brain tissu patient
ad well lung diseas ischem heart cancer diabet compel evid suggest
rage act inflammatori intermediari critic induc oxid stress
underli pathophysiolog chang drive process ad specif
rage may import contributor gener enhanc activ and/or
interact srage appear inhibit neurotox promot
clearanc brain addit rage appear promot factor synapt dysfunct
neuron circuit dysfunct materi structur cognit physiolog
patholog basi lastli rage appear trigger pathogenesi
tau hyper-phosphoryl implic process cognit impair
effect attenu follow antagon rage receptor
increas express advanc glycat end product age interact rage result
increas reactiv oxygen speci ro direct caus brain
ro increas synthesi high-mobl group box protein regul
transcript involv organ dna play role inflamm cell differenti
tumor cell migrat ro also increas level famili involv aspect
regul cell prolifer differenti apoptosi ca homeostasi energi metabol
inflamm migrat ligand interact rage result addit ro
result involv ad patholog achiev reduct level
rage elev solubl rage srage may benefici therapeut modal
prevent regress slow progress ad
post-mortem studi ad patient reveal increas rage express neuron microgli
endotheli cell compar normal cell around senil plaqu express higher level
rage diseas progress furthermor express level rage correl
sever diseas data observ human ad patient consist result multipl
non-clin vitro vivo model show rage overexpress brain taken
togeth believ scientif literatur provid substanti support rage inhibit
valid promis therapeut approach treatment ad
differenti oral anti-diabet drug potenti help
fda recogn unmet need patient diabet patient difficulti
achiev maintain consist level glycem control recommend
american diabet associ achiev maintain blood glucos level close
normal level possibl mg/dl meal less mg/dl two
hour meal multipl oral anti-diabet drug oad approv manag high
blood glucos hyperglycemia accomplish inject insulin treatment option
approv achiev compar result insulin peptid hormon produc
beta cell pancreat islet believ oral administ small molecul liver-select
glucokinas agonist develop oad treatment diabet high-valu phase
stage asset demonstr novel mechan action studi show patient
treat achiev sustain meaning reduct
optim glycem control fundament manag diabet regardless
underli treatment level associ significantli increas risk
microvascular cardiovascular cv evid indic improv glycem
control reduc risk complic persist long-term control dcct trial
one largest clinic trial ever conduct diabet
signific reduct cv outcom non-fat myocardi infarct mi stroke cv death
well all-caus mortal previous intens treat particip compar
standard similarli ukpd trial signific reduct mi
all-caus mortal cohort particip random intens
result studi also indic tight control retard develop
diabet market one largest still one unmet medic need research
found estim current size global diabet therapeut market rang billion
billion expect grow compound-annual-growth-rate howev ada estim
total cost diagnos diabet healthcar system billion
purpos report focu diabet therapeut market diabet market
huge diabet deadli epidem diabet seventh lead caus death
 death certif list diseas underli caus death
death certif list diabet underli contribut caus death
million peopl popul diabet approxim million
howev diabet may under-report peopl diabet die
diabet list anywher death certif diabet list
underli caus
specif diabet treatment use depend type diabet bodi immun
system attack destroy beta cell result insulin produc product greatli
reduc glucos accumul blood may caus seriou damag organ
insulin inject infus via pump devic remain standard care insulin regul
metabol carbohydr fat protein promot absorpt carbohydr especi
glucos blood liver fat skelet muscl cell convert glycogen fat
circul insulin also affect synthesi protein wide varieti tissu insulin resist ir
condit defect action insulin normal level insulin trigger
signal glucos absorpt excess free fatti acid ffa implic pathogenesi
ir effect condit profound pathophysiolog effect variou organ
tissu bodi exampl ir associ impair insulin signal impair fibrinolysi
hypertens dyslipidemia metabol syndrom cardiovascular diseas pharmacotherapi
target ir includ metformin thiazolidinedion endocannabinoid antagonist agent target
obes associ cardiovascular metabol risk factor current develop
complex metabol disord beta cell unabl properli regul blood
glucos within limit patient compris overal diabet major
drug develop diabet focus larg varieti mechan action
target result larg number drug approv includ megltinid
receptor agonist bile acid sequestr inhibitor receptor agonist amylin analog
approv combin medicin
despit avail multipl oral therapi introduct new oral therapi
inhibitor novel mechan treatment use monotherapi
combin agent remain lack differenti inadequ efficaci
inject receptor agonist gener consid superior efficaci compar
approv oad primari care physician patient continu prefer oral agent eas
use improv patient complianc versu inject remain unmet medic need
oral drug mimic superior efficaci receptor agonist reduc incid
hypoglycemia expect competit non-insulin therapi market
specif market compris oad inject receptor agonist
mechan action may complementari exist treatment comorbid
associ diabet vtv chosen develop diabet drug two differ approach
one approach stimul receptor phase stage pipelin asset
agonist approach activ glucokinas gk target
phase studi patient gk activ demonstr anim model
reduc mechan action entir distinct current market oad
gk activ attract potenti new therapi treatment
multitud oad market thu vtv chosen near-term focu intern diabet
program develop therefor potenti up-front mileston royalti
payment vtv partner model contribut revenu time
gk act physiolog glucos sensor chang conform activ intracellular locat
parallel chang glucos concentr gk two main distinct characterist make
good choic blood glucos control first express mostli limit tissu requir
glucose-sens liver pancreat beta cell second direct chang serum glucos
level gk modul chang liver glucos metabol turn regul balanc
hepat glucos product glucos consumpt modul chang insulin secret beta
studi human along numer anim studi show mutat gene encod gk
caus hyperglycemia diabet mellitu hypoglycemia glucos level normal
depend mutat confirm critic role gk regul glucos
concept gk activ treatment diabet attract proven
effect safe normal glycemia anim model mechan entir distinct
action anti-diabet therapi current moreov sever line evid
suggest develop may specif relat function impair gk
thu gk activ may way overcom import underli caus
progress henc halt delay cours diseas
may profil superior previous identifi gk agonist drug candid number
compani tri develop gk agonist gka drug result gka drug candid
competitor yabao pharmaceut rate privately-held pegbio hua medicin
rate teijin pharma tinli rate evalu clinic
treatment demonstr improv glucos control howev gka show increas
incid hypoglycemia hyperlipidemia appar lack durabl efficaci unfavor
profil gka correl glucose-independ hyper-stimul beta cell
accumul lipid liver consist disrupt gk activ interact gk
regulatori protein gkrp control intracellular locat gk contrast vtv liver-select
compound activ gk pancreat beta cell affect gk interact gkrp
liver moreov show potenti normal level without contraind
renal impair littl risk pancreat furthermor found safe test
diabet frequent diagnos treat number comorbid
cardiovascular diseas hyperlipidemia result mechan action appear
complementari exist treatment comorbid associ diabet
advantag support strong evid base compris clinic trial
includ nine phase studi healthi volunt subject two phase trial
earli result on-going phase trial
exhibit result agata phase trial
august vtv complet agata phase clinic trial six-month trial
demonstr poc benefit could sustain time agata multi-
center adapt phase random double-blind placebo- activ sitagliptin -control parallel
group trial evalu safeti efficaci follow six month administr
subject subject stabl dose metformin subject baselin
agata includ subject across four arm includ two dose mg
mg sitagliptin inhibitor market treatment name januvia
merck placebo agata chang baselin six month key
secondari endpoint chang weight result agata show treatment daili administr
mg result statist signific chang baselin six month
reduct dose-depend sustain throughout durat studi
also found well-toler advers event sever hypoglycemia
hyperlipidemia report group
novemb vtv initi adapt phase trial assess
pharmacokinet pharmacodynam safeti toler adult patient simplici-
conduct partnership jdrf august enter research
develop commerci agreement vtv support entail fund
studi includ payment million base achiev research develop
mileston accord agreement vtv oblig make certain mileston payment jdrf
upon commerci licens sale transfer treatment
design evalu whether well-toler administ add-on
insulin therapi improv daili glucos profil peopl live vtv
complet enrol part learn phase phase portion studi
design double-blind placebo-control studi evalu week daili dose mg
chang expect result june part phase portion
studi posit catalyst stock vtv begun start-up activ part
confirm phase phase portion expect report result late
expect result portion studi posit catalyst stock
look vtv conduct end-of-phas meet fda lead approv
initi pivot phase trial adult make note due larg
patient popul involv chronic natur treatment diabet natur expect
regulatori approv requir outcom studi accept standard industri
outcom studi often take three year complet involv thousand patient prior
market author howev expect clinic develop follow regulatori path
navig lexicon pharmaceut rate zynquista inhibitor
market treatment europ gain ema approv septemb without
support outcom studi look regulatori approv estim billion
annual sale could achiev
remaind product pipelin compris early-stag asset whose develop
think materi de-risk via synergist out-licens agreement
vtv product pipelin contain early-stag asset
includ contribut model think vtv unlock valu
asset form licens agreement return moder payment vtv grant partner
right product candid certain territori vtv retain right europ
japan vtv primari market interest think payment materi de-risk vtv
early-stag asset partner either sole respons develop case
reneo newsoara respect case
huadong sole respons late-stag develop product candid navig
foreign licens countri regulatori process initi partnership advanc
product candid mid-stag clinic trial think vtv agreement partner
notabl show synergist relationship think provid best chanc near-term
advanc asset provid vtv data compani could use attract partner
develop rest world
huadong potenti make biggest invest agreement includ
conduct phase trial china decemb vtv enter licens
agreement hangzhou zhongmei huadong pharmaceut huadong obtain
exclus sub-licens licens develop commerci vtv glucagon-lik
receptor agonist compound includ therapeut use human
anim china certain pacif rim countri includ australia south korea addit
agreement vtv obtain non-exclus sub-licens royalty-fre licens develop
commerci certain huadong patent right know-how relat vtv program
therapeut use human anim outsid huadong licens territori term
agreement huadong paid vtv initi licens fee million vtv elig receiv potenti
develop regulatori mileston payment total million addit potenti
regulatori mileston million huadong receiv regulatori approv central nervou
system indic addit vtv elig addit million potenti sales-bas
mileston well royalti payment rang low-singl low-doubl digit rate base tier
sale licens product
huadong agreement vtv respons conduct phase multi-region clinic trial
includ site unit state huadong licens territori purpos assess
safeti efficaci patient design phase trial expect
satisfi requir china food drug administr order huadong begin
phase clinic trial china vtv respons contribut million connect
phase trial huadong respons develop commerci licens
product huadong licens territori huadong cost requir use reason effort
respect develop effort huadong requir use commerci reason
effort develop commerci least one compound china
unless termin huadong agreement expect continu product-by-product country-
by-countri basi expir royalti oblig huadong owe vtv licens product
extend later expir certain patent data exclus right cover licens
product eight year first commerci sale licens product countri
parti uncur materi
breach huadong may termin agreement upon prior written notic subject certain time
restrict relat phase clinic trial
agreement
reneo total payment highest absolut term potenti highli lucr
expect target orphan indic decemb vtv enter licens
agreement reneo pharmaceut reneo obtain exclus world-wide sub-
licens licens develop commerci vtv peroxisom prolifer activ receptor delta
ppar- agonist program includ compound therapeut prophylact
diagnost applic human term agreement reneo paid vtv initi licens fee
million vtv elig receiv addit potenti develop regulatori sales-bas
mileston payment total million reneo also oblig pay royalti payment mid-
singl low-doubl digit rate base tier annual net sale licens product part
reneo agreement vtv receiv common stock certain particip right repres minor
interest reneo outstand equiti term agreement reneo respons
world-wide develop commerci licens product cost requir use
commerci reason effort respect develop commerci effort unless
termin agreement expir royalti oblig reneo vtv
made either parti may termin agreement parti uncur materi breach reneo
may termin agreement upon prior written notic upon expir earlier termin
agreement licens grant reneo surviv royalty-fre basi perpetu
newsoara intend advanc estim billion chronic obstruct
pulmonari diseas copd market china may vtv enter licens agreement
newsoara biopharma newsoara obtain exclus sub-licens licens
develop commerci vtv phosphodiesteras type inhibitor compound includ
china certain pacif rim countri agreement vtv obtain non-
exclus sub-licens royalty-fre licens develop commerci certain newsoara patent
right know-how relat vtv program therapeut use human outsid
term agreement newsoara paid vtv up-front cash payment million vtv
elig receiv addit potenti develop regulatori sales-bas mileston payment
total million addit newsoara oblig pay vtv royalti payment high-singl
low-doubl digit rate base tier annual net sale licens product royalti
payabl licens product-by-licens product country-by-countri basi latest
expir licens patent cover licens product countri expir data exclus
right licens product countri undisclos specif number year first
commerci sale licens product countri
term agreement newsoara respons develop commerci
licens product newsoara licens territori newsoara cost requir use
commerci reason effort respect develop commerci effort
newsoara agreement unless termin earlier continu expir royalti oblig
newsoara vtv either parti may termin newsoara licens agreement parti
uncur materi breach newsoara may termin agreement upon prior written notic upon
expir earlier termin agreement licens grant newsoara expect
surviv royalty-fre basi perpetu
kametani hasegawa front neurosci
glenner wong biochem biophi
hardi selko scienc
budson solomon memori loss alzheim diseas dementia edit
prasad mol cell biochem may doi epub ahead print
bailey grant lancet
 wilson front physiol
use discount cash flow dcf methodolog arriv price target
vtvt share specif discount free cash flow year vtv weighted-averag cost
capit wacc divid project number share year account
effect share dilut use termin growth rate adjust probability-of-success
deriv adjust per share valu round assumpt made
fda ema pmda regulatori approv azeliragon alzheim diseas patient
million adult million adult rest world row alzheim
approxim ad patient
approxim ad patient diabet
peak penetr azeliragon ad patient diabet treat
project price wholesal acquisit cost wac monthli prescript
would approxim midway cost monthli prescript aricept fda
approv patch fda approv
patient refil monthli prescript azeliragon time per year
azeliragon achiev annual sale million ex-u annual sale billion
fda ema pmda regulatori approv type diabet
million peopl million row
approxim patient receiv
peak penetr patient treat ex-u
project price wholesal acquisit cost wac monthli prescript
reflect slight premium monthli cost jardianc fda approv slight
discount monthli cost farxiga fda approv monthli cost
invokana fda approv
patient refil monthli prescript time per year
achiev annual sale million ex-u annual sale billion
discount rate vtv
termin growth rate adjust annual price increas popul growth
grow incid adult seriou thought suicid year
lastli adjust probabl approv incorpor success rate drug
develop observ drug like azeliragon central nervou system
diseas disord observ drug like metabol
compani report wainwright co estim
alzheim diseas royalti licens total sales- depreci stock-bas interest provis incom taxes- chang work free number share per termin valu per share- round todiscount growth npv per npv termin valu per valu per probabl probabl vtv therapeut inc
clinic although demonstr efficaci safeti compani drug candid
unproven pivot clinic trial design meet fda requir approv possibl
compani drug candid fail phase test materi affect valuat
regulatori even drug candid meet predefin primari outcom measur phase test
possibl addit inform addit trial could requir regul
address linger safeti efficaci concern occur could significantli delay revenu
gener go forward materi affect forecast
commerci success develop azeliragon critic compani
success compani fail delay develop commerci compani busi
prospect oper result would suffer stock price would like declin
competit compani candid fail show differenti possibl may
competit thu doctor may continu favor use current therapi current treatment
regimen could materi affect forecast
intellectu properti commerci success compani drug candid depend
strength patent protect compani technolog risk compani patent
could invalid competitor expir prior product approv significantli diminish
compani abil realiz product revenu lead posit cash flow
anticip compani current cash posit adequ
compani unabl sign partner mitig cost clinic develop product candid
decid advanc product candid pivot trial addit fund could
requir complet studi
compani report wainwright co estim
incom statement fiscal year end decemb except per share product royalti licens total good sold- gross oper oper incom interest incom expens expens relat incom loss pre-tax incom tax benefit expens net incom loss non-controlling net loss attribut non-controlling net loss attribut deem distribut relat party- net loss attribut common ep weight averag inc
compani report wainwright co estim
incom statement fiscal year end decemb except per share product alzheim diseas diabet diabet royalti licens total good sold- gross oper oper incom interest incom expens expens relat incom loss pre-tax incom tax benefit expens net incom loss non-controlling net loss attribut non-controlling net loss attribut deem distribut relat party- net loss attribut common ep weight averag inc
compani report wainwright co estim
incom depreci stock compens capit free net chang inc
compani report wainwright co estim
balanc sheet cash restrict cash cash current deposits- account receiv inventories- prepaid expens current current total current total redeem non-controlling sharehold liabil inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori vtv inc vtvt-u
rate price target histori inc biib-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
vernon bernardino certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli relat
specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
 wainwright co llc manag co-manag public offer secur inc past
firm make market inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
